Related references
Note: Only part of the references are listed.Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban
Kengo Noguchi et al.
BLOOD COAGULATION & FIBRINOLYSIS (2015)
Laboratory Measurement of the Anticoagulant Activity of the Non-Vitamin K Oral Anticoagulants
Adam Cuker et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin
Jeanne Mendell et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
Robert P. Giugliano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects
Nobuko Matsushima et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2013)
Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents
Toshio Fukuda et al.
THROMBOSIS AND HAEMOSTASIS (2012)
In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux
Meyer Michel Samama et al.
THROMBOSIS RESEARCH (2012)
QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies
Penny F. Whiting et al.
ANNALS OF INTERNAL MEDICINE (2011)
Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers
Jeanne Mendell et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation
Namsik Chung et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux
Michael Wolzt et al.
THROMBOSIS AND HAEMOSTASIS (2011)
Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers
Koichiro Ogata et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation
Jeffrey I. Weitz et al.
THROMBOSIS AND HAEMOSTASIS (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
Share Paper
